Narrative Update on GeneDx Holdings
Analysts have raised their price target for GeneDx Holdings from $123.75 to $127.22. This change reflects improved expectations for revenue growth and profit margins in upcoming periods.
What's in the News
- GeneDx selected as a partner for Florida's new Sunshine Genetics Act, the first state-backed genomic newborn screening program offering whole-genome sequencing for up to 100,000 newborns over five years (Client Announcements).
- Launch of BEACONS, a $14.4 million multi-state study with GeneDx as sequencing partner, aiming to pilot whole-genome sequencing in newborn screening programs across up to 10 U.S. states (Product-Related Announcements).
- GeneDx introduces Infinity, the largest rare disease dataset, to pediatricians at the AAP National Conference, enhancing diagnosis and research for rare diseases (Product-Related Announcements).
- Announcement of the Autism Partnership Program to expand access to exome and genome testing for autism and Phelan-McDermid syndrome, with Jaguar Gene Therapy as founding partner (Client Announcements).
- Full-year 2024 revenue guidance increased to $400 to $415 million, up from previous $360 to $375 million (Corporate Guidance Raised).
Valuation Changes
- Consensus Analyst Price Target has risen slightly, increasing from $123.75 to $127.22.
- Discount Rate remains unchanged at 6.78%.
- Revenue Growth expectation has increased moderately, moving from 19.67% to 20.17%.
- Net Profit Margin estimate has grown modestly, rising from 17.83% to 18.25%.
- Future P/E ratio has declined slightly, moving from 43.53x to 43.19x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.